Clinical Trial Update: A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks [Phase 3]

View source ↗

Summary

Phase 3 trial comparing nivolumab dosing regimens (240 mg every 2 weeks vs 480 mg every 4 weeks) in advanced/metastatic non-small cell lung cancer patients who …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2020-06-22